Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002
Background. Treatment results of acute lymphoblastic leukemia in children on protocol, developed by one of the leading research study group BFM (Berlin-Frankfurt-Munster) are impressive - longstanding overall survival rate comprise 93.4 %. The basis of success is a differential approach based on pro...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/568 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409240948539392 |
|---|---|
| author | T. T. Valiev M. A. Shervashidze T. S. Belysheva |
| author_facet | T. T. Valiev M. A. Shervashidze T. S. Belysheva |
| author_sort | T. T. Valiev |
| collection | DOAJ |
| description | Background. Treatment results of acute lymphoblastic leukemia in children on protocol, developed by one of the leading research study group BFM (Berlin-Frankfurt-Munster) are impressive - longstanding overall survival rate comprise 93.4 %. The basis of success is a differential approach based on prognostic factors. In some local issues BFM protocols receive criticism because of high toxicity, but trying to find results of complex protocol toxicity assessment by modern scales in local literature, it was absent.Aim. To study a toxicity of acute lymphoblastic leukemia treatment by ALL IC-BFM 2002 protocol.Materials and methods. 119 patients with primary diagnosed acute lymphoblastic leukemia were enrolled the study. All the patients were treated by ALL IC-BFM 2002 protocol. Toxicity assessment was performed by the scale of National Cancer Institute (NCI) USA, 2nd version.Results. The most often variants of toxicity during treatment according to the ALL IC-BFM 2002 protocol were myelo-suppression, infections and hepatotoxicity of I-IV degrees of severity. Clinically significant toxicity (grade IV) was myelosuppression and necessity for transfusions in 76.8-100 % (depending on prognostic risk group and as such protocol arm). Nephro- and hepatotoxicity described on high-dosed methotrexate (2000 mg/m2 or 5000 mg/m2) were I-II grade in 89.5 % patients. Stomatitis grade I-II was in 93.7 % patients of standard and intermediate risk groups, but in the most (90 %) patients from high risk group it was higher - grade III-IV. Mortality on protocol ALL IC-BFM 2002 caused by infection complications was 1.6 %. It should be noted, that supportive care, prescribed in ALL IC-BFM 2002 protocol help to prevent and correct severe toxicity effectively.Conclusion. The toxicity profile of ALL IC-BFM 2002 protocol, analyzed by frequency of toxicity grade III-IV with whole supportive care approaches, is acceptable. The noted variants of toxicity were fully resolved without irreversible consequences for the patients. |
| format | Article |
| id | doaj-art-da2cd625d25f421da8149f10612b3204 |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-da2cd625d25f421da8149f10612b32042025-08-20T03:35:33ZrusABV-pressОнкогематология1818-83462413-40232022-07-0117313715910.17650/1818-8346-2022-17-3-137-159461Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002T. T. Valiev0M. A. Shervashidze1T. S. Belysheva2Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaResearch Institute of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaBackground. Treatment results of acute lymphoblastic leukemia in children on protocol, developed by one of the leading research study group BFM (Berlin-Frankfurt-Munster) are impressive - longstanding overall survival rate comprise 93.4 %. The basis of success is a differential approach based on prognostic factors. In some local issues BFM protocols receive criticism because of high toxicity, but trying to find results of complex protocol toxicity assessment by modern scales in local literature, it was absent.Aim. To study a toxicity of acute lymphoblastic leukemia treatment by ALL IC-BFM 2002 protocol.Materials and methods. 119 patients with primary diagnosed acute lymphoblastic leukemia were enrolled the study. All the patients were treated by ALL IC-BFM 2002 protocol. Toxicity assessment was performed by the scale of National Cancer Institute (NCI) USA, 2nd version.Results. The most often variants of toxicity during treatment according to the ALL IC-BFM 2002 protocol were myelo-suppression, infections and hepatotoxicity of I-IV degrees of severity. Clinically significant toxicity (grade IV) was myelosuppression and necessity for transfusions in 76.8-100 % (depending on prognostic risk group and as such protocol arm). Nephro- and hepatotoxicity described on high-dosed methotrexate (2000 mg/m2 or 5000 mg/m2) were I-II grade in 89.5 % patients. Stomatitis grade I-II was in 93.7 % patients of standard and intermediate risk groups, but in the most (90 %) patients from high risk group it was higher - grade III-IV. Mortality on protocol ALL IC-BFM 2002 caused by infection complications was 1.6 %. It should be noted, that supportive care, prescribed in ALL IC-BFM 2002 protocol help to prevent and correct severe toxicity effectively.Conclusion. The toxicity profile of ALL IC-BFM 2002 protocol, analyzed by frequency of toxicity grade III-IV with whole supportive care approaches, is acceptable. The noted variants of toxicity were fully resolved without irreversible consequences for the patients.https://oncohematology.abvpress.ru/ongm/article/view/568acute lymphoblastic leukemiatreatmentpolychemotherapybfmtoxicitychildren |
| spellingShingle | T. T. Valiev M. A. Shervashidze T. S. Belysheva Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 Онкогематология acute lymphoblastic leukemia treatment polychemotherapy bfm toxicity children |
| title | Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 |
| title_full | Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 |
| title_fullStr | Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 |
| title_full_unstemmed | Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 |
| title_short | Toxicity assessment of acute lymphoblastic leukemia treatment protocol ALL IC-BFM 2002 |
| title_sort | toxicity assessment of acute lymphoblastic leukemia treatment protocol all ic bfm 2002 |
| topic | acute lymphoblastic leukemia treatment polychemotherapy bfm toxicity children |
| url | https://oncohematology.abvpress.ru/ongm/article/view/568 |
| work_keys_str_mv | AT ttvaliev toxicityassessmentofacutelymphoblasticleukemiatreatmentprotocolallicbfm2002 AT mashervashidze toxicityassessmentofacutelymphoblasticleukemiatreatmentprotocolallicbfm2002 AT tsbelysheva toxicityassessmentofacutelymphoblasticleukemiatreatmentprotocolallicbfm2002 |